Weekly Funding Opportunities

[med-Research]

PhRMA Foundation: Research Starter Grants in Drug Discovery and Drug Delivery
Drug Discovery<http://www.phrmafoundation.org/awards/research-starter-grants/drug-discovery/>
The PhRMA Foundation Research Starter Grant in Drug Discovery offers financial support to individuals beginning independent research careers at the faculty level in drug discovery research. $100,000 for one-year projects. Those holding the academic rank of assistant professor (or research assistant professor) within a tenure track (or research track) appointment, or instructor, if eligible to apply for independent research funding by their institution, are eligible to apply for these research starter grants, providing their proposed research is neither directly nor indirectly already being subsidized to any significant degree by an extramural support mechanism. Individuals receiving only intramural funding or start-up funding from their institution are eligible to apply for Research Starter Grant (RSG) awards.
Drug Delivery<http://www.phrmafoundation.org/awards/research-starter-grants/drug-delivery/>
The PhRMA Foundation Research Starter Grant in Drug Delivery offers financial support to individuals beginning independent research careers at the faculty level in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology or biomedical engineering. $100,000 for one-year projects. Those holding the academic rank of assistant professor (or research assistant professor) within a tenure track (or research track) appointment, or instructor, if eligible to apply for independent research funding by their institution, are eligible to apply for these research starter grants, providing their proposed research is neither directly nor indirectly already being subsidized to any significant degree by an extramural support mechanism. Individuals receiving only intramural funding or start-up funding from their institution are eligible to apply for Research Starter Grant (RSG) awards.
Letter of intent due May 20, 2021. Med-RA deadline to receive draft documents: May 10.

Alzheimer’s Drug Discovery Foundation: Accelerating Drug Discovery for Frontotemporal Degeneration<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd>
There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD) and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). Drug targets in the areas of inflammation and proteostasis will be considered high priority.
The RFP supports:

  *   Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
  *   In vivo testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.
One-year projects; $100,000-$150,000 based on stage and scope of research.
Letter of intent due May 28, 2021. Med-RA deadline to receive draft documents: May 17.

When Everyone Survives Foundation: Leukemia Research Grants<https://www.wheneveryonesurvives.org/grant_application>
This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of “When Everyone Survives”.  Renewal of initial research support may be considered for one or more additional years based upon productivity.
Due June 1, 2021. Med-RA deadline to receive draft documents: May 18.

Genentech: Scientific Project Support<https://www.gene.com/good/giving/corporate-giving/scientific-project-support>
Scientific Project Support provides funding for general research, translational research, other research or development projects, and/or other initiatives of research organizations, labs, and academic institutions. As part of our company-wide commitment to ensuring a healthier future for all patients, we prioritize projects that build a more fair and just healthcare system in the following areas:

  *   Inclusive research: Reducing barriers to participation in clinical trials so healthcare solutions are designed for all patients
  *   Equity in care: Ensuring all patients have access to high quality care
  *   Future life sciences workforce: Create sustainable pathways into the life sciences for underrepresented groups, particularly low-income students of color
Research collaborations, clinical trials, and associated correlative research involving or undertaken in relation to Genentech or Roche products (whether investigational and/or approved for other uses) are excluded from this type of support.
Genentech prioritizes action-oriented research projects that are designed to build the evidence base needed to promote health equity and reduce disparities in healthcare access, quality, and outcomes amongst populations facing the greatest needs. Evidence generated from Scientific Projects should support health systems and hospitals, practitioners, advocates, and decision-makers in setting priorities and allocating resources towards solutions that improve the health and wellbeing of all patients within Genentech’s disease areas of focus.
Operating expenses must be directly and exclusively dedicated to the activity for which the requestor is applying. Genentech/Roche will consider funding requests in the following disease states: bladder cancer, breast cancer, metastatic breast cancer, HER2-positive metastatic breast cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancy, hemophilia, leukemia, lung cancer, lymphoma, waldenstrom’s macroglobulinemia, melanoma, multiple sclerosis, myeloma, non-hodgkins lymphoma, ovarian cancer, and pan-tumor.
Applications accepted any time. Med-RA deadline to receive draft documents: ten business days before submission to sponsor.

Foundation for OCD Research: Seed Grants<https://www.ffor.org/grants>
FFOR is seeking applications for innovative, potentially high-impact pre-clinical, translational or clinical research from investigators around the world. We seek to support projects that have the potential to significantly advance the understanding of the pathophysiology of OCD and/or improve the treatment of severe OCD. Examples of relevant research include, but are not limited to studies that aim to:

  *   Discover the molecular, cellular, synaptic, or circuit basis of prominent OCD symptoms in model organisms or humans.
  *   Identify and/or test pharmacological and non-pharmacological therapeutic targets.
  *   Advance biomarker development for OCD to improve diagnoses and/or treatment outcomes.
  *   Explore the role of the immune system or microbiome in OCD.
  *   Develop new models or refine existing models of OCD
3-year projects, $200,000 a year in direct costs, 10% IDC.
Letter of intent due June 15, 2021. Med-RA deadline to receive draft documents: June 2.

Robert Wood Johnson Foundation: Transforming Health and Health Care Systems<https://www.rwjf.org/en/library/funding-opportunities/2021/research-in-transforming-health-and-health-care-systems.html?rid=0034400001rm2ZLAAY&et_cid=2453106>
The purpose of this Transforming Health and Health Care Systems call for proposals is to fund research studies that evaluate or predict how enrollees are effected by Medicaid policy changes enacted in response to the COVID-19 pandemic. Given the disproportionate impact of the pandemic on communities of color, we are requesting studies that examine the impact of Medicaid policies on communities of color and/or explore how current or proposed policies may alleviate or exacerbate racial inequity and structural racism in the context of Medicaid. The goal of this funding opportunity is to generate rigorous evidence on the effects of recent Medicaid policy changes on enrollees, states, and others, and to inform and advance equitable policies and racial equity in Medicaid.
Due June 28, 2021. Med-RA deadline to receive draft documents: June 15.

Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Black Children and Adolescents (R34 / R01 Clinical Trial Optional)
R34<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-186.html>
This initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among Black children and adolescents. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects. Research generating new information about factors causing/reducing disparities is strongly encouraged, along with due consideration for the variation in developmental needs across children and youth. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This Funding Opportunity Announcement (FOA) invites development of interventions and strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the future implementation of interventions that are proven effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the intervention under development should account for individual-, family-, community-, provider-, and organizational-level factors necessary to optimize effectiveness, feasibility, and rapid uptake, implementation, and sustained delivery, thereby accelerating the benefit to the population. The intervention should also improve connections to preventive and treatment interventions with proven effectiveness in reducing suicide and suicidal ideation and behaviors, with the goal of making these interventions more available, accessible, and more effectively delivered to Black youth, in a sustained and coordinated way. This FOA encourages pilot research focused on the development of systems-level interventions and is not intended to support development or testing of new screening tools, assessment instruments, or pilot studies for the development of individual-level preventive or therapeutic interventions.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-185.html>
This initiative supports research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) among Black children and adolescents. Specifically, this Funding Opportunity Announcement (FOA) encourages services research on the effectiveness-implementation continuum aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI, among Black children and adolescents. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This FOA invites testing of interventions and strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the systems-level interventions and strategies should also account for individual-, family-, community-, provider-, and organizational-level factors to optimize the effectiveness, feasibility, and rapid uptake, implementation, and sustained delivery, thereby accelerating the benefit to the population. This research should also improve connections to preventive and treatment interventions with proven effectiveness in reducing SIB or NSSI, with the goal of making these interventions more available, accessible, and more effectively delivered to Black youth, in a sustained and coordinated way. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions.
Due June 29, 2021. Med-RA deadline to receive draft documents: June 16.

Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R34 / R01 Clinical Trial Optional)
R34<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-188.html>
This initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among children and adolescents from underserved populations. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects. Research generating new information about factors causing/reducing disparities is strongly encouraged, along with due consideration for the variation in developmental needs across children and youth. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This Funding Opportunity Announcement (FOA) invites development of service  strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the future implementation of interventions that are proven effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social and contextual factors, the service strategy under development should account for individual-, family, community-, provider-, and organizational-level factors necessary to optimize effectiveness, feasibility, and rapid uptake, implementation  and sustained delivery, thereby accelerating the benefit to the population. The intervention should improve connections to preventive and treatment interventions with proven effectiveness in reducing suicide and suicidal ideation and behaviors, with the goal of making these more available, accessible, and more effectively delivered to underserved youth, in a sustained and coordinated way. This FOA encourages pilot research focused on the development of systems-level interventions and is not intended to support development or testing of new screening tools, assessment instruments, or pilot studies for the development of individual-level preventive or therapeutic interventions.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-187.html>
This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) by youth from populations that are often underserved by the mental health system. Specifically, this Funding Opportunity Announcement (FOA) encourages services research aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI among adolescents and children from the targeted populations. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. The service strategies to be tested under this announcement should be designed for delivery in typical service settings using commonly available personnel and resources, to enhance implementation and future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the intervention strategies should account for individual-, family-, community-, provider-, and organizational-level factors to optimize effectiveness, feasibility, acceptability, rapid uptake and sustained delivery. The strategy should also improve connections to preventive and treatment interventions with proven effectiveness in reducing SIB or NSSI, with the goal of making these interventions more available, accessible, and more effectively delivered to youth, in a sustained and coordinated way. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions.
Due June 29, 2021. Med-RA deadline to receive draft documents: June 16.

National Institute for Health Care Management (NIHCM) Foundation Investigator-Initiated Health Services Research Grants<https://nihcm.org/grants/research-grants>
NIHCM Foundation supports innovative investigator-initiated research with high potential to inform improvements to the U.S. health care system. Projects must advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy.
Letter of inquiry due June 30, 2021. Med-RA deadline to receive draft documents: June 18.

L.I.F.E. Foundation Research Grants: Brain and Neurodegenerative Diseases<https://life-brainhealth.org/grant.html>
George J. Wile established the Local Initiative for Excellence (L.I.F.E.) Foundation in 2014 with a mission to support research to achieve better health outcomes for patients with brain and neurodegenerative disease. The L.I.F.E. Foundation provides research grants to support innovative research, to sustain productive research teams and to encourage and support investigators in the early part of their career. Proposals should focus on basic research to advance understanding of how the brain functions, and proposals exploring how COVID impacts basic brain function will also be considered. The L.I.F.E. Foundation plans to fund up to two grants of $100,000 each (to be awarded over two years $50,000 per year) for reimbursement of approved research expenditures.
Brain cancer research and clinical research will not be considered for funding.
Letter of intent due June 30, 2021. Med-RA deadline to receive draft documents: June 18.

BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R34 / R01 Clinical Trial Not Allowed)
R34<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-014.html>
This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects – TargetedBCP R01 (below). Applications should be adventurous exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-013.html>
This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.
Due July 7, 2021 and November 10, 2021. Med-RA deadline to receive draft documents for July 7 due date: June 23 (due to July 4 holiday).

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-008.html>
This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021.
Due July 7, 2021. Med-RA deadline to receive draft documents: June 23 (due to July 4 holiday).

Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-009.html>
High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations<https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs#radx-up> (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.
Due July 7, 2021. Med-RA deadline to receive draft documents: June 23 (due to July 4 holiday).

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-012.html>
The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Outcomes such as generated tools and data collection by these projects will enhance the overall goals of the IDG Program by expanding the resources available for the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.
Due July 15, 2021. Med-RA deadline to receive draft documents: July 1 (due to July 4 holiday).

Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-020.html>
Related: Notice of Special Interest (NOSI) for Illuminating the Druggable Genome (IDG) Initiative: Request for Administrative Supplements to Existing Grants for incorporating single cell data into the IDG Knowledgebase<https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-019.html> (NOSI expires June 16, 2021.)
The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program “Illuminating the Druggable Genome” (IDG;https://commonfund.nih.gov/idg/ is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium’s Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community’s ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos(https://pharos.nih.gov/idg/index)that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community. The IDG consortium’s purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC).
Due July 15, 2021. Med-RA deadline to receive draft documents: July 1 (due to July 4 holiday).

End the HIV Epidemic (R01s)
Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-023.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
Due July 30, 2021. Med-RA deadline to receive draft documents: July 19.
Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-024.html>
The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the goals of the DIAGNOSE and TREAT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement.
Due August 4, 2021. Med-RA deadline to receive draft documents: July 22.
Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-025.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities.
Due July 30, 2021. Med-RA deadline to receive draft documents: July 19.

Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-013.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues.  A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy.
Due July 30, 2021. Med-RA deadline to receive draft documents: July 19.

Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-009.html>
This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.
Due July 30, 2021. Med-RA deadline to receive draft documents: July 19.

Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61 / R33 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-012.html>
This Funding Opportunity Announcement (FOA) encourages exploratory and developmental bi-phasic research. Applications are solicited to support the understanding of post-transcriptional regulation of intact and defective HIV RNA and to develop therapeutic strategies to alter RNA post-transcriptional modifications as a potential therapeutic platform for inhibiting HIV replication.
Due August 4, 2021. Med-RA deadline to receive draft documents: July 22.

Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3 / UH3 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-018.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV acquisition: men who have sex with men (MSM), people who inject drugs (PWID), and transgender women and men, focusing especially on the minority and age groups at highest risk of HIV transmissions. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV acquisition, comparing those who become HIV-positive to those who do not, and optionally to develop and test digitally-delivered interventions that promote HIV risk reduction to reduce HIV-incidence.
Due August 4, 2021. Med-RA deadline to receive draft documents: July 22.

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-208.html>
The National Institute on Drug Abuse (NIDA<https://www.drugabuse.gov/>) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA’s current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.
Due August 10, 2021; March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; and March 8, 2024. Med-RA deadline to receive draft documents for August 10, 2021 due date: July 28.

Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-019.html>
Research funded by this initiative will examine the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop medical countermeasures (MCMs) for radiation exposure. Through this initiative, the NIAID Radiation and Nuclear Countermeasures Program (RNCP) will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways.
Due August 24, 2021. Med-RA deadline to receive draft documents: August 11.

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer’s Disease and Related Dementias (AD/ADRD) (R61 / R33 and R01 Clinical Trial Optional)
R61 / R33<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-016.html>
This Funding Opportunity Announcement invites R61/R33 applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stage I-IV) behavior change trials. Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD.
Due September 15, 2021. Med-RA deadline to receive draft documents:  September 1 (due to Labor Day holiday).
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-21-207.html>
This Funding Opportunity Announcement (FOA) invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that – if modified – will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study.
Due September 15, 2021 and January 26, 2022. Med-RA deadline to receive draft documents for September 15 due date: September 1 (due to Labor Day holiday).

Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 / R01 – Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/pa-files/PAS-21-215.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAS-21-216.html>
These Funding Opportunity Announcements solicit applications for research projects that will advance translational research to better understand risk and resilience for suicide in the context of the NIMH Research Domain Criteria (RDoC) framework, specifically the Positive Valence Systems (PVS) domain, and lead to novel interventions. The projects should focus on the identification of novel behavioral or neurobiological intervention targets for the treatment of suicidality. NIMH is particularly interested in the role of PVS deficits in suicidal thoughts and behaviors, identification of unique subtypes by behavior and neural circuitry, and associations between PVS-related subtypes and other RDoC domains in relation to suicidality.
Due October 5, 2021. Med-RA deadline to receive draft documents: September 22.

Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-196.html>
The goal of the Innovative Programs to Enhance Research Training (IPERT) initiative is to enable the scientific community to develop and implement innovative educational activities to equip diverse cohorts of participants with technical, operational or professional skills required for careers in the biomedical research workforce, by effectively integrating the required core elements described below:

  *   Courses for Skills Development: For example, support for short courses designed to develop technical (e.g., appropriate and safe methods, technologies, and quantitative/computational approaches), operational (e.g., independent knowledge acquisition, rigorous experimental design, and interpretation of data) and/or professional (e.g., management, leadership, communication, and teamwork) skills necessary to conduct rigorous and reproducible research, and to transition successfully into careers in the biomedical research workforce. These courses could be in-person or provided electronically. Dissemination of educational materials and outreach activities to benefit individuals from a variety of backgrounds are required components of the program.
  *   Mentoring Activities: For example, activities designed to provide career information, advice, and support to research-oriented undergraduates, graduate students, postdoctoral fellows, or independent faculty in biomedical fields. The activities should provide participants with a perspective on the biomedical research training pathway and tools for overcoming challenges, navigating career transition points, and successfully transitioning into careers in the biomedical research workforce.
Due October 14, 2021; October 14, 2022; and October 13, 2023. Med-RA deadline to receive draft documents for October 14, 2021 due date: October 4.

Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-006.html>
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell interventions using novel cell sources, immune-modulatory strategies, biomaterials and devices for T1D treatment.
Due October 20, 2021. Med-RA deadline to receive draft documents: October 7.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210421/62522dab/attachment.html>